Skip to main content
Premium Trial:

Request an Annual Quote

MDxHealth, Merck KGaA Extend Deal for Cancer Trial

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – MDxHealth today announced the extension of a deal with Merck KGaA for the use of its MGMT assay in Merck's brain cancer drug clinical trials.

Merck is currently engaged in a Phase III trial for its integrin inhibitor cilengitide for newly diagnosed patients with glioblastoma with a methylated promoter of the methylguanine-DNA methyltransferase, or MGMT, gene in the tumor tissue. MGMT gene promoter testing at MDxHealth's laboratories is required before patient enrollment in the trial called CENTRIC, the first prospective international controlled Phase III oncology trial that is using the MGMT assay as a standard for determining the patient population for a trial, MDxHealth said.

The new agreement continues a deal between MDxHealth and Merck that started with the CENTRIC trial in 2008. Merck also is conducting a randomized controlled Phase II study called CORE with cilengitide in newly diagnosed glioblastoma patients.

The CORE trial also is using the MGMT assay to stratify patients. However, participants in that trial require an unmethylated status of the MGMT promoter in the tumor, whereas patients in the CENTRIC trial require a positive methylation status of the MGMT gene promoter.

Financial and other terms of the alliance were not disclosed.

The Scan

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.

DNA Storage Method Taps Into Gene Editing Technology

With a dual-plasmid system informed by gene editing, researchers re-wrote DNA sequences in E. coli to store Charles Dickens prose over hundreds of generations, as they recount in Science Advances.

Researchers Model Microbiome Dynamics in Effort to Understand Chronic Human Conditions

Investigators demonstrate in PLOS Computational Biology a computational method for following microbiome dynamics in the absence of longitudinally collected samples.

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.